SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update on Tuesday, March 18 at 8:00 a.m. ET at the Cowen and Company 28th Annual Healthcare Conference in Boston, Massachusetts. Stephen A. Sherwin, chairman and chief executive officer of Cell Genesys, will present a company update on March 18 at 10:15 a.m. ET at the Lehman Brothers 11th Annual Global Healthcare Conference in Miami, Florida.
A live audio webcast of both presentations will be accessible through the Investor Relations section of the Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.
Cell Genesys is focused on the development and commercialization of
novel biological therapies for patients with cancer. The company is
currently pursuing two clinical stage product platforms -- GVAX(TM) cancer
immunotherapies and oncolytic virus therapies. Ongoing clinical trials
include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2
trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and
a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell
Genesys continues to hold an equity interest in its former subsidiary,
Ceregene, Inc., which is developing gene therapies for neurodegenerative
disorders. Cell Genesys is headquartered in South San Francisco, CA and has
its principal manufacturing operation in Hayward, CA. For additional
information, please visit the company's website at
|SOURCE Cell Genesys, Inc.|
Copyright©2008 PR Newswire.
All rights reserved